Atlas Trials

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

Clinical trial NCT04377555 · COMPLETED

Trial details

NCT number
NCT04377555
Sponsor
Genentech, Inc.
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Multiple Sclerosis, Relapsing
Start date
2020-07-30
Primary completion
2022-12-15
Enrollment
179

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.